Lantern Pharma Reports Complete Metabolic Response in Phase 1 Trial of LP-284 for Aggressive DLBCL

Lantern Pharma (NASDAQ: LTRN) has announced a significant milestone in its ongoing Phase 1 trial of LP-284, a next-generation acylfulvene, with the observation of a complete metabolic response in a patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This patient, who had previously failed three prior treatments including CAR-T and bispecific antibody therapy, responded after just two cycles of LP-284. This development underscores the potential of LP-284's synthetic lethal mechanism to revolutionize treatment for refractory lymphomas, positioning it as a promising candidate in the $4 billion global B-cell cancer market.

The success of LP-284 is attributed to Lantern Pharma's proprietary RADR(R) AI platform, which utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms to accelerate drug discovery and development. This innovative approach has enabled Lantern Pharma to advance its drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years, at an average cost of approximately $2.5 million per program. For more details on this breakthrough, visit https://ibn.fm/TCGHH.

This announcement not only highlights the efficacy of LP-284 but also demonstrates the transformative potential of AI in oncology drug development. By leveraging cutting-edge technology, Lantern Pharma is setting a new standard for the speed and cost-effectiveness of bringing life-saving treatments to market. The implications of this development extend beyond the immediate benefits to patients with refractory lymphomas, offering a glimpse into the future of cancer treatment where AI-driven platforms like RADR(R) play a pivotal role in identifying and developing novel therapies.